First Command Advisory Services Inc. Purchases 418 Shares of Pfizer Inc. (NYSE:PFE)

First Command Advisory Services Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 2.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 17,479 shares of the biopharmaceutical company’s stock after acquiring an additional 418 shares during the period. First Command Advisory Services Inc.’s holdings in Pfizer were worth $464,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Proficio Capital Partners LLC grew its position in shares of Pfizer by 2,193.2% in the fourth quarter. Proficio Capital Partners LLC now owns 225,584 shares of the biopharmaceutical company’s stock valued at $5,985,000 after purchasing an additional 215,747 shares during the last quarter. Mn Services Vermogensbeheer B.V. lifted its holdings in shares of Pfizer by 2.1% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 2,230,300 shares of the biopharmaceutical company’s stock worth $59,170,000 after buying an additional 46,200 shares in the last quarter. New York Life Investment Management LLC grew its stake in shares of Pfizer by 1.2% in the fourth quarter. New York Life Investment Management LLC now owns 786,520 shares of the biopharmaceutical company’s stock valued at $20,866,000 after acquiring an additional 9,007 shares in the last quarter. Allegiance Financial Group Advisory Services LLC bought a new position in Pfizer during the fourth quarter worth about $231,000. Finally, Cable Hill Partners LLC raised its stake in Pfizer by 20.5% in the 4th quarter. Cable Hill Partners LLC now owns 21,344 shares of the biopharmaceutical company’s stock worth $566,000 after purchasing an additional 3,632 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

Shares of PFE opened at $26.40 on Thursday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $149.63 billion, a PE ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. The stock has a 50-day moving average of $26.34 and a 200-day moving average of $27.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the firm posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PFE shares. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.